Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00803972 · ClinicalTrials.gov registry record · Phase 1
Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20
A Phase 1 study, sponsored by Halozyme Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00803972 is a Phase 1 study that has completed, run by Halozyme Therapeutics. The registered enrollment target is 42 participants.
The verdict
NCT00803972, a Phase 1 study, has completed, sponsored by Halozyme Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a single center, Phase I, open-label, single-blind (subjects blinded to the contents of each injection), 4 stage study designed to determine the PK, GD, safety, tolerability, and optimal ratio of rHuPH20 administered with fixed Humulin R or Humalog doses in healthy subjects.
Interventions
- DRUG rHuPH20
- DRUG Insulin Human Injection
- DRUG Insulin Lispro Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-08-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00803972
The ClinicalTrials.gov registry entry for NCT00803972 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Halozyme Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which rHuPH20 is the first listed.
NCT00803972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00803972 about?
NCT00803972 is a clinical study titled "Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20". This is a single center, Phase I, open-label, single-blind (subjects blinded to the contents of each injection), 4 stage study designed to determine the PK, GD, safety, tolerability, and optimal ratio of rHuPH20 administered with fixed Humulin R or Humalog doses in healthy subjects.
What is the current status of trial NCT00803972?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2008-11. Estimated completion is 2009-08-28.
What interventions are being tested in trial NCT00803972?
The interventions under investigation include: rHuPH20 (DRUG), Insulin Human Injection (DRUG), Insulin Lispro Injection (DRUG).
Who is sponsoring clinical trial NCT00803972?
This trial is sponsored by Halozyme Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.